FDA Orders Suicide Warnings On Epilepsy Drugs
Makers of epilepsy drugs must now add a warning that states the medicines carry a risk of suicidal thoughts or actions. The companies must also develop a patient-friendly guide explaining the risks.
In January 2008 the Food and Drug Administration (FDA) warned that 11 epilepsy drugs doubled a person’s risk of suicidal behaviors or thoughts. In December 2008 the FDA announced it would be mandatory to place this warning on all eleven drug containers.
The 11 epilepsy drugs that must now include a warning are:
- Lyrica
- Neurontin
- Lamictal
- Topamax
- Carbatrol
- Felbatol
- Keppra
- Trileptal
- Gabitril
- Depakote
- Zonegran
Epilepsy drugs were the fifth best-selling class of drugs in the U.S. in 2007 with sales exceeding 10 billion dollars. In addition to treating epilepsy, the anti-seizure drugs are also used for nerve-pain disorders, migraines, and psychiatric diseases such as bipolar disorder.
The FDA voted not to make the warning on the containers a “black box warning,” the strongest of its kind, as doctors and other outside experts advised that it could do more harm than good if patients in need of treatment were to stop using the drugs. It is, however, recommended that patients consult with their doctors before making any changes to their treatment, or if they have any questions about their medication.
The Law Offices of Joe Bornstein is working with highly respected national counsel in an effort to assist the family and relatives of anyone who has committed suicide or serious attempt cases while taking any of the above medications. Please phone our office at 1-800-772-4624 to speak with one of our staff members if this alert applies to you and your family.
For more information on epilepsy drugs, their risks, and all advisories, please visit: www.fda.org.
